AMICUS THERAPEUTICS INC 4
4 · AMICUS THERAPEUTICS INC · Filed Jul 1, 2015
Insider Transaction Report
Form 4
Gershkowitz Jayne
VP, Patient Advocacy
Transactions
- Sale
Common stock
2015-07-01$13.97/sh−10,649$148,818→ 5,693 total - Exercise/Conversion
Common stock
2015-07-01$13.97/sh+10,649$148,818→ 16,342 total - Exercise/Conversion
Stock Options (right to buy)
2015-07-01−3,463→ 28,075 totalExercise: $2.52From: 2014-06-18Exp: 2023-06-18→ Common stock (3,463 underlying) - Exercise/Conversion
Stock Options (right to buy)
2015-07-01−4,374→ 26,252 totalExercise: $3.53From: 2014-01-28Exp: 2023-01-28→ Common Stock (4,374 underlying) - Exercise/Conversion
Stock Options (right to buy)
2015-07-01−2,812→ 39,376 totalExercise: $2.45From: 2015-01-03Exp: 2024-01-03→ Common stock (2,812 underlying)
Footnotes (3)
- [F1]The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- [F2]This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.87 to $14.15. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F3]This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.87 to $14.15. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.